A Phase II Trial of BIBF1120 in Patients with Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and Renal Pelvis and Who Have Failed Platinum-Based Chemotherapy (I)

Project title

以BIBF1120治療晚期膀胱、尿道、輸尿管、腎盂泌尿上皮癌病患(其腫瘤的纖維母細胞生長因子受體有基因突變、蛋白質過度表現或兩者皆無，而且以包含白金的化學治療已經失敗)的第二期臨床試驗(I)

Internal ID

MOST103-2325-B002-018

Principal Investigator

Start Date

February 1, 2014

End Date

January 31, 2015

Organizations

Partner Organizations